Population-based analysis of class effect of b blockers in XXXX .

@entity1 @entity712 @entity10719 @entity1405 @entity1406 @entity2165 @entity204 @entity2179
The long-term use of b blockers has been shown to improve the outcomes of @entity1 with @entity712 ( @entity712 ). However, it is still disputed whether this is a class effect, and, specifically, whether @entity1405 or @entity2179 are superior to @entity1406 . The present study was a comparative effectiveness study of b blockers for @entity1 with @entity712 in a population-based setting. We conducted an observational cohort study using the Quebec administrative databases to identify @entity1 with @entity712 who were prescribed a b blocker after the diagnosis of @entity712 . We used descriptive statistics to characterize the @entity1 by the type of b blocker prescribed at discharge. The unadjusted mortality for users of each b blocker was calculated using Kaplan-Meier curves and compared using the log-rank test. To account for differences in follow-up and to control for differences among @entity1 characteristics, a multivariate Cox proportional hazards model was used to compare the mortality. Of the 26,787 @entity1 with @entity712 , with a median follow-up of 1.8 years per @entity1 , the crude incidence of @entity204 was 47% with @entity1406 , 40% with @entity2165 , 41% with @entity1405 , 36% with @entity2179 , and 43% with @entity10719 . After controlling for several different covariates, we found that @entity1405 (hazard ratio [HR] 1.04, 95% confidence interval [CI] 0.97 to 1.12, p = 0.22) and @entity2179 (HR 0.96, 95% CI 0.91 to 1.01, p = 0.16) were not superior to @entity1406 in improving survival. @entity2165 (HR 0.82, 95% CI 0.77 to 0.87, p <0.0001) and @entity10719 (HR 0.86, 95% CI 0.78 to 0.95, p = 0.004) were superior to @entity1406 . In conclusion, we did not find evidence of a class effect for b blockers in @entity1 with @entity712 .
